MX9702524A - Virus atenuados y metodo para elaborarlos. - Google Patents
Virus atenuados y metodo para elaborarlos.Info
- Publication number
- MX9702524A MX9702524A MX9702524A MX9702524A MX9702524A MX 9702524 A MX9702524 A MX 9702524A MX 9702524 A MX9702524 A MX 9702524A MX 9702524 A MX9702524 A MX 9702524A MX 9702524 A MX9702524 A MX 9702524A
- Authority
- MX
- Mexico
- Prior art keywords
- attenuated viruses
- genome
- making
- virus
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen virus atenuados, que no ocurren naturalmente, que contienen uno o más sitios de metilacion adicionales en el genoma del virus, en comparacion con el virus tipo silvestre correspondiente. De preferencia los sitios de metilacion son agregados en el genoma del virus introduciendo un segmento CG adicional en el genoma por medio de una mutilacion silent. Los virus atenuados son utiles para producir una respuesta inmune, incluyendo tanto la produccion de anticuerpos en animales para uso de diagnostico como para la induccion de inmunidad protectora en un sujeto. También se describen formulaciones farmacéuticas y métodos para elaborar los virus atenuados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08319974 | 1994-10-07 | ||
US08/319,974 US20030104576A1 (en) | 1994-10-07 | 1994-10-07 | Dna construct, composition, formulations & methods for making the construct & for modulating expression |
PCT/US1995/013219 WO1996011280A1 (en) | 1994-10-07 | 1995-10-05 | Attenuated viruses and method of making the same |
Publications (2)
Publication Number | Publication Date |
---|---|
MXPA97002524A MXPA97002524A (es) | 1998-02-01 |
MX9702524A true MX9702524A (es) | 1998-02-28 |
Family
ID=23244339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9702524A MX9702524A (es) | 1994-10-07 | 1995-10-05 | Virus atenuados y metodo para elaborarlos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030104576A1 (es) |
EP (1) | EP0784692A1 (es) |
JP (1) | JPH10507077A (es) |
KR (1) | KR970706399A (es) |
CN (1) | CN1169161A (es) |
CA (1) | CA2201487A1 (es) |
MX (1) | MX9702524A (es) |
NO (1) | NO971495L (es) |
NZ (1) | NZ295070A (es) |
WO (1) | WO1996011280A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
ES2322172T3 (es) * | 2004-05-26 | 2009-06-17 | Biovaxim Limited | Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas. |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
CN101045946B (zh) * | 2007-04-29 | 2010-09-29 | 深圳市疾病预防控制中心 | Hiv基因检测芯片及其制备方法 |
AR063866A1 (es) * | 2007-11-20 | 2009-02-25 | Consejo Nac Invest Cient Tec | Un procedimiento para la obtencion de cepas virales atenuadas |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
MX359314B (es) | 2011-08-30 | 2018-09-25 | Astex Pharmaceuticals Inc Star | Formulaciones derivadas de decitabina. |
WO2013104995A2 (en) | 2012-01-12 | 2013-07-18 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
AU2013213345A1 (en) | 2012-01-27 | 2014-08-28 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
ES2784351T3 (es) * | 2015-05-18 | 2020-09-24 | Calimmune Inc | Métodos de discriminación entre el VIH-1 y vectores de lentivíricos |
WO2017004538A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
CN113186353A (zh) * | 2021-05-28 | 2021-07-30 | 杭州晶佰生物技术有限公司 | 针对c型逆转录病毒的数字pcr检测用引物及检测方法 |
-
1994
- 1994-10-07 US US08/319,974 patent/US20030104576A1/en not_active Abandoned
-
1995
- 1995-10-05 CN CN95196131A patent/CN1169161A/zh active Pending
- 1995-10-05 NZ NZ295070A patent/NZ295070A/xx unknown
- 1995-10-05 CA CA002201487A patent/CA2201487A1/en not_active Abandoned
- 1995-10-05 EP EP95936339A patent/EP0784692A1/en not_active Withdrawn
- 1995-10-05 WO PCT/US1995/013219 patent/WO1996011280A1/en not_active Application Discontinuation
- 1995-10-05 KR KR1019970702279A patent/KR970706399A/ko not_active Application Discontinuation
- 1995-10-05 JP JP8512719A patent/JPH10507077A/ja not_active Ceased
- 1995-10-05 MX MX9702524A patent/MX9702524A/es unknown
-
1997
- 1997-04-02 NO NO971495A patent/NO971495L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1996011280A1 (en) | 1996-04-18 |
NO971495L (no) | 1997-05-26 |
EP0784692A1 (en) | 1997-07-23 |
NZ295070A (en) | 1999-11-29 |
AU707782B2 (en) | 1999-07-22 |
CA2201487A1 (en) | 1996-04-18 |
JPH10507077A (ja) | 1998-07-14 |
CN1169161A (zh) | 1997-12-31 |
AU3832795A (en) | 1996-05-02 |
US20030104576A1 (en) | 2003-06-05 |
KR970706399A (ko) | 1997-11-03 |
NO971495D0 (no) | 1997-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9702524A (es) | Virus atenuados y metodo para elaborarlos. | |
PT835133E (pt) | Composições recombinantes de poxvírus-raiva e composições de combinação e suas utilizações | |
ATE454163T1 (de) | Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren | |
HU9302575D0 (en) | Dendritical macromolecules and process for preparation thereof | |
ES8203226A1 (es) | Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos. | |
TR200202448T2 (tr) | Genetik olarak oluşturulmuş uçuk aşısı | |
MY125202A (en) | Vaccine | |
WO1996011279A3 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system | |
EP1077719A4 (en) | VACCINE DELIVERY SYSTEM | |
IL138424A (en) | Covalently reactive antigen analogs and pharmaceutical compositions containing the same | |
FI964592A (fi) | Papilloomavirusrokotteita | |
ES8505719A1 (es) | Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas | |
CA2094515A1 (en) | Bacterial Attenuation Method and Vaccine | |
ES2179261T3 (es) | Vacuna a base de streptococcus equi. | |
IL73428A0 (en) | Anti-idiotype antibodies against a tumor or virus,method and cell lines for producing them and compositions containing them | |
CA2185470A1 (en) | Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes | |
DK0478602T3 (da) | Ekspression af tetanus toxin fragment C | |
PL332540A1 (en) | Method of inducing active immunity using a vaccine conjugate | |
AU2002217043A1 (en) | Salmonella vaccine | |
BG102809A (en) | Vaccine against the reproductive and respiratory syndrome in pigs | |
AU7237391A (en) | Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine | |
EP0868522A4 (en) | RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE | |
DE69836520D1 (de) | Clostridium perfringens Impfstoff | |
NZ238833A (en) | Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom | |
TW200502384A (en) | Live attenuated bacteria of the species actinobacillus pleuropneumoniae |